The MDM2–p53 axis is also regulated by multiple, parallel oncogenic signaling pathways implicated in sarcomagenesis, and these pathways might represent valuable targets for combination therapeutic strategies in DDLPS. Here, MDM2 is linked to dedifferentiated liposarcoma.